The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | RASolute 304: adjuvant daraxonrasib vs observation in resected PDAC
Michel Ducreux, MD, PhD, Paris-Saclay University, Paris, France, describes the design of the Phase III RASolute 304 trial (NCT07252232) of adjuvant daraxonrasib, an oral RAS(ON) multi-selective inhibitor, versus observation following neoadjuvant and/or adjuvant chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC). Patients will be randomized to daraxonrasib or standard-of-care observation, with disease-free survival as the primary endpoint. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
